A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs BIIB 059 (Primary)
- Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms LILAC
- Sponsors Biogen
- 24 Aug 2017 Planned number of patients changed from 290 to 320.
- 21 Feb 2017 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
- 21 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.